BioPreviously, Dr. Herlihy served as CEO and President of Repligen from 1996 to 2015. Under his leadership, Repligen grew from a market capitalization of approximately $20 million to in excess of $1 billion and became one of the leading bioprocessing companies in the United States. Repligen was one of the earliest investments made by BMVF.
Education